New drug RLF-100 shows dramatic recovery in COVID-19 patients suffering respiratory failure

Aviptadil is a formulation of Vasoactive Intestinal Polypeptide (VIP), which is present in high concentrations in the lungs and known to block various inflammatory cytokines. NeuroRx and Relief Therapeutics have partnered to develop the drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/31jpFcG
via IFTTT